Browse by author
Lookup NU author(s): Dr Michael Laker, Dr R Neely
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Recent data are reviewed in relation to three topics in Lipidology, the investigation of dyslipidaemia, recent statin trials and novel lipid lowering agents. There is increasing evidence to support the use lipid variables such as apolipoprotein (apo) B and non-HDL cholesterol in addition to LDL cholesterol in the assessment of dyslipidaemia. However, it is premature to suggest that apoB and non-HDL cholesterol concentrations should replace LDL cholesterol as the primary lipid measurement for CHD risk assessment. The Heart Protection Study shows impressive benefits from statin treatment at lower lipid levels than those recommended for treatment by current guidelines. Atorvastatin has now been added to simvastatin and pravastatin as HMG-CoA reductase inhibitors for which favourable outcome data have been published, through the lipid-lowering arm of the ASCOT Study. Ezetimibe, a cholesterol absorption inhibitor, has recently been licensed for use. It reduces LDL cholesterol by up to 25 % when administered as a single daily dose, either as monotherapy or in combination with a statin. Ezetimibe may prove to have a role as monotherapy in patients who are intolerant to statins and in combination with a statin in refractory hypercholesterolaemia.
Author(s): Laker MF, Neely RDG
Publication type: Review
Publication status: Published
Journal: CPD Bulletin Clinical Biochemistry
Year: 2003
Volume: 5
Issue: 3
Pages: 75-79
Print publication date: 01/01/2003
ISSN (print): 1367-8930
ISSN (electronic):
